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Transient high-grade bacteremia following invasive procedures carries a risk of infective endocarditis (IE).
This is supported by experimental endocarditis. On the other hand, case-control studies showed that IE could
be caused by cumulative exposure to low-grade bacteremia occurring during daily activities. However, no
experimental demonstration of this latter possibility exists. This study investigated the infectivity in animals
of continuous low-grade bacteremia compared to that of brief high-grade bacteremia. Rats with aortic vege-
tations were inoculated with Streptococcus intermedius, Streptococcus gordonii or Staphylococcus aureus (strains
Newman and P8). Animals were challenged with 103 to 106 CFU. Identical bacterial numbers were given by
bolus (1 ml in 1 min) or continuous infusion (0.0017 ml/min over 10 h). Bacteremia was 50 to 1,000 times
greater after bolus than during continuous inoculation. Streptococcal bolus inoculation of 105 CFU infected 63
to 100% vegetations compared to 30 to 71% infection after continuous infusion (P> 0.05). When increasing the
inoculum to 106 CFU, bolus inoculation infected 100% vegetations and continuous infusion 70 to 100% (P >
0.05). S. aureus bolus injection of 103 CFU infected 46 to 57% valves. This was similar to the 53 to 57% infection
rates produced by continuous infusion (P > 0.05). Inoculation of 104 CFU of S. aureus infected 80 to 100%
vegetations after bolus and 60 to 75% after continuous infusion (P > 0.05). These results show that high-level
bacteremia is not required to induce experimental endocarditis and support the hypothesis that cumulative
exposure to low-grade bacteremia represents a genuine risk of IE in humans.
Because of its severity, it is generally agreed that infective
endocarditis (IE) should be prevented whenever possible.
Over the last 50 years, guidelines of IE prophylaxis were edited
by numerous international medical societies, which proposed
antibiotic prophylaxis in a great number of patients and med-
ico-surgical situations. However, this was without a definite
proof of efficacy and without evaluation of its real its cost-
benefit ratio (2, 3, 13, 23, 43). In fact, it was suggested that
applying antibiotic prophylaxis systematically might be more
detrimental than beneficial (36, 38).
Since studying IE prophylaxis in human raised ethical issues
and would require too many patients (6), animal models were
established to mimic the disease and test antibiotic prophylaxis
(7). Moreover, for experimental reliability, animals were inoc-
ulated with large bacterial numbers, producing IE in 90%
untreated individuals (12). Successful antibiotic prophylaxis in
such stringent conditions were reinsuring for the medical com-
munity. However, although this assumption is likely to be cor-
rect, case-control studies and meta-analyses showed that most
cases of IE occurred outside the context of dental or other
medico-surgical procedures, independently of prophylaxis ad-
ministration (28, 37, 39, 40). Thus, medico-surgical interven-
tions may only represent one anecdotic event among other
factors that should be taken into account in IE development.
Although it is true that dental or other surgical procedures
may cause bacteremia (16, 29), routine daily events, such as
mastication and tooth brushing, can also result in bacteremia
as well (1, 11, 19–21, 29). It was estimated that the cumulative
numbers of circulating bacteria (in CFU/ml/year) resulting
from either mastication, tooth brushing two times daily or
mere dental examination, were up to 5.6 million times, 154,000
times, and 48 times greater than that provoked by a single
tooth extraction (14, 32, 42, 43). Thus, cumulative low-grade
bacteremia might equal or surpass sporadic procedure-related
bacteremia as a risk for IE induction.
Considering all of these arguments, guidelines of IE prophy-
laxis were recently revisited and greatly simplified, both in the
United States and in Europe (15, 43, 44). The resulting sim-
plified guidelines have positive implications, and they identify
a great proportion (90%) of at-risk patients that should not
take routine antibiotic prophylaxis, because they might not
benefit from it. On the other hand, they are also frustrating,
because they do not propose any prevention in these 90% of
patients that are at risk of developing IE spontaneously.
To address this issue, we must improve our understanding of
disease initiation. Indeed, while there is general agreement
that recurrent low-grade bacteremia is likely to promote IE,
there is no knowledge of the relative risk of IE represented by
such type of bacteremia compared to transient high-grade bac-
teremia induced by procedures. Moreover, in case of low-grade
bacteremia, there is not much knowledge about possible ag-
gravation factors, such as the carriage of particular IE patho-
gens (e.g., Staphylococcus aureus versus Streptococcus spp.) or
concomitant inflammatory or immunological conditions, that
might favor bacterial colonization of undamaged endothelia
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via endothelial expression of integrins (25) or alter microbial
clearance from the blood.
The present study addressed the first of these questions by
comparing the rates of experimental IE in rats with catheter-
induced aortic vegetations after (i) transient high-grade bacte-
remia, mimicking procedure-induced bacteremia, or (ii) con-
tinuous low-grade bacteremia, simulating the cumulative
exposure to bacteremia from daily life activities during a long
period of time, for instance, 1 year (32). Animals were chal-
lenged with either bolus injection (over 1 min) or continuous
infusion (over 10 h) with similar bacterial numbers (from 103
to 106 CFU) of viridans streptococci or S. aureus. The infec-
tivity rate of continuous low-grade bacteremia was not differ-
ent from that of transient high-grade bacteremia. Since the
continuous low-grade condition is closer of the common situ-
ation in humans, it provides a new model to study endocarditis
pathogenesis and novel preventive strategies.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Four well-described bacterial isolates
were used, including two types of viridans group streptococci (i.e., Streptococcus
intermedius and Streptococcus gordonii) (8, 12) and two types of S. aureus (i.e.,
methicillin-susceptible S. aureus [MSSA] Newman and methicillin-resistant S.
aureus [MRSA] P8) (9, 24). Streptococci were grown at 37°C with 5% CO2 in
brain heart infusion broth (Difco/Becton Dickinson, Sparks, MD) and S. aureus
at 37°C in tryptic soy broth (Difco). Bacterial stocks were kept at70°C in liquid
medium supplemented with 20% (vol/vol) of glycerol.
Animal studies. All animal experiments were carried out according to Swiss
regulations (authorization, 879.6). For all manipulations, animals were anesthe-
tized with a mixture of ketamine (75 mg/kg) and midazolam (0.5 mg/kg) given
intraperitoneally. Catheter-induced sterile aortic vegetations were produced in
female Wistar rats as previously described (17). In parallel, an intravenous (i.v.)
line was inserted via the jugular vein into the superior vena cava and connected
to a programmable infusion pump (Pump 44; Harvard Apparatus, Inc., South
Natick, MA) in order to deliver the inocula (10).
Bacterial inocula were prepared from overnight cultures. Microorganisms
were recovered by centrifugation, washed, and adjusted to the desired inoculum
size in saline. The inoculum size was confirmed by colony counts on blood agar
plates. Animals were inoculated 24 h after catheterization, via the infusion pump,
by either of two distinct protocols. In protocol 1, they received an i.v. bolus (1 ml
in 1 min) containing inoculum sizes capable of infecting 50% and 90% of the
vegetations. These inoculum sizes were 105 to 106 CFU for viridans streptococci
and 103 to 104 CFU for S. aureus (8, 9, 12, 24). In protocol 2, animals received
the same total absolute numbers of bacteria as in protocol 1 but progressively
delivered at a pace of 0.0017 ml/min over 10 h. During this period, no growth of
the original inoculum used for challenge was observed, as checked in preliminary
experiments.
To evaluate the concentrations of bacteria in the blood, 1 ml of blood was
drawn from selected animals by puncturing the external jugular vein, using
aseptic procedures, and collected in heparin-containing tubes. Samples were
taken just before inoculation, 1 min and 2 h (for bolus injection) or 2 and 6 h (for
continuous infusion) after inoculation onset. The 1-min time point for bolus
injection corresponded to the timing of blood cultures in previous human and
animal studies (31, 33). The 2- and 6-h time points for continuous infusion were
chosen on the basis of numerous pilot experiments, which showed that the
continuous-infusion technique yielded stable bacteremia levels over time. Blood
was serially diluted in saline and spread onto Columbia blood agar plates, which
were incubated for 48 h at 37°C before colony counts. The sensitivity of the
method was 1 CFU/ml of blood.
Rats were sacrificed 24 h after the end of inoculation. Quantitative valve and
spleen cultures were performed as previously described (8). This method per-
mitted the detection of 2 log10 CFU/g of vegetation and 1 log10 CFU/g of spleen.
Statistical analysis. The percentages of valve and spleen infection following
bolus and continuous infusion were compared by the Fisher exact test. Median
bacterial counts in vegetations and spleens in the bolus and continuous infusion
groups were compared by the Mann-Whitney rank sum test. Statistical analyses
were performed with GraphPad Prism software (version 4.0; GraphPad Soft-
ware, San Diego, CA). Differences were considered significant when P was 
0.05 by use of two-tailed significance levels.
RESULTS
Bacteremia levels and rates of vegetation and spleen infec-
tion for viridans streptococci. The intensity of bacteremia and
the percentage of infected vegetations are shown in Fig. 1.
Blood cultures were all negative before bacterial inoculation
(baseline). Bolus inoculation of 105 CFU S. intermedius or S.
gordonii was followed by bacteremia levels ranging between
5  103 and 9  103 CFU/ml 1 min after inoculation. In
comparison, the median (range) levels of bacteremia during
continuous infusion were 1,000 times lower, i.e., 4 (0 to 20) for
S. intermedius and 1 (0 to 7) CFU/ml for S. gordonii. Bactere-
mia levels 1 min after bolus injection of 106 CFU S. intermedius
or S. gordonii was 10 times greater than after 105 CFU, i.e.,
between 2  104 and 9  104 CFU/ml for both test organisms,
and yet negative 2 h later. In comparison, bacteremia levels
during continuous infusion had median values of 10 (range, 1
to 24) CFU/ml and 9 (range, 1 to 18) CFU/ml for S. intermedius
and S. gordonii, respectively.
Figure 1 also depicts the related rates of infection. Bolus
injection of 105 CFU resulted in 5 of 8 (63%) and 8 of 8
(100%) infected vegetations for S. intermedius and S. gordonii,
respectively, compared to 3 of 10 (30%; P  0.34) and 12 of 17
(71%; P 0.14) after continuous infusion. When the inoculum
size was increased to 106 CFU, bolus inoculation infected 6 of
6 (100%) and 8 of 8 (100%) vegetations with both strains,
respectively, compared to 7 of 10 (70%) and 6 of 6 (100%)
infected vegetations after continuous infusion (P  0.05).
With regard to spleen infection, bolus injection of 105 CFU
resulted in 6 of 8 (75%) and 5 of 6 (83%) positive cultures for
S. intermedius and S. gordonii, respectively, compared to 2 of 8
(25%; P  0.13) and 5 of 16 (31%; P  0.06) after continuous
infusion. At the inoculum size of 106 CFU, bolus inoculation of
S. intermedius and S. gordonii infected 5 of 5 (100%) and 8 of
8 (100%) spleens, respectively, compared to 4 of 8 (50%) and
6 of 6 (100%) after continuous infusion (P  0.05).
Bacteremia levels and rates of vegetation and spleen infec-
tion for S. aureus. As in the streptococcal experiments, all
blood cultures were negative before bacterial inoculation. The
intensity of bacteremia and the percentage of infected vegeta-
tions are shown in Fig. 2. One minute after bolus injection of
103 CFU, the median CFU/ml of blood values (ranges) were 49
(8 to 140) for MSSA Newman and 56 (10 to 86) for MRSA P8.
No circulating bacteria were detected 2 h later. In contrast, the
same inoculum injected in continuous infusion produced bac-
terial concentrations in the blood ranging only between 0 to 2
CFU/ml of blood but lasting for 10 h. Also, as in streptococci,
bolus inoculation of 104 CFU produced 10-fold greater levels
of bacteremia at 1 min, with medians (ranges) of 473 (120 to
1,110) CFU/ml for MSSA Newman and 510 (240 to 1,400)
CFU/ml for MRSA P8. No circulating bacteria were detectable
after 2 h. This compares to medians of 2 (0 to 2) CFU/ml for
MSSA Newman and 3 (0 to 15) CFU/ml for MRSA P8 during
continuous infusion.
Figure 2 also depicts the corresponding results of valve in-
fections. Bolus injection of 103 CFU resulted in 8 of 14 (57%)
and 6 of 13 (46%) of infected valves with MSSA Newman and
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MRSA P8, respectively. This was very similar to the rate of
valve infection produced by continuous infusion, i.e., 8 of 15
(53%) for MSSA Newman and 8 of 14 (57%) for MRSA P8
(P  0.05 compared to bolus injection), in spite of much lower
levels of circulating bacteria. This similarity of infection rates
persisted after increasing the inoculum by 10 times (i.e., 104
CFU), in spite of even greater differences (100 times) in
bacteremia levels. MSSA Newman and MRSA P8 infected 8 of
FIG. 1. Level of bacteremia and resulting vegetation infection in rats challenged with 105 and 106 CFU of Streptococcus intermedius or
Streptococcus gordonii. Identical inoculum sizes were given by i.v. bolus (1 ml in 1 min) or continuous infusion (0.0017 ml/min over 10 h). The
symbols (Œ and }) indicate median and range values.
FIG. 2. Level of bacteremia and resulting vegetation infection in rats challenged with 103 and 104 CFU of MSSA Newman or MRSA P8.
Identical inoculum sizes were given by i.v. bolus (1 ml in 1 min) or continuous infusion (0.0017 ml/min over 10 h). The symbols (Œ and }) indicate
median and range values.
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10 (80%) and 8 of 8 (100%) vegetations after bolus inoculation
and 9 of 12 (75%) and 9 of 15 (60%) after continuous infusion,
respectively (P  0.05).
Spleen cultures after bolus injection of 103 CFU were pos-
itive in 14 of 14 (100%) and 8 of 13 (62%) animals infected
with MSSA Newman and MRSA P8, respectively, which was
not significantly different from the rate of spleen infection
produced by continuous infusion, i.e., 13 of 15 (87%) for
MSSA Newman and 10 of 14 (71%) for MRSA P8 (P  0.05).
After the inoculum of MSSA Newman and MRSA P8 was
increased by 10 times (i.e., 104 CFU), spleens were infected in
10 of 10 (100%) and 8 of 8 (100%) animals after bolus infec-
tion and 11 of 12 (92%) and 11 of 15 (74%) animals after
continuous infusion, respectively (P  0.05).
Bacterial densities in infected tissues. The animals were also
analyzed for the ability of bacteria to multiply in infected
vegetations and spleens after having colonized the tissue. Ta-
ble 1 shows that, at the time of sacrifice, bolus- and continuous
infusion-challenged animals had no significantly different bac-
terial densities in the vegetations and spleens (P 0.05). How-
ever, in infected vegetations the number of CFU tended to be
higher in the bolus groups than in the continuous-infusion
groups. This is likely due to the different number of bacteria
colonizing the valves early after inoculation. Since at that time
the level of circulating bacteremia is much higher after bolus,
more bacteria are allowed to colonize and multiply in the
vegetations than after continuous infusion.
DISCUSSION
The results in the present study show that low-grade contin-
uous bacteremia produced infections in experimental IE that
were not significantly different from those resulting from tran-
sient high-grade bacteremia. This suggests that the most im-
portant predictor of valve infection is not the peak level of
circulating bacteria but rather the area under the curve over
time. Indeed, bacteremia levels of ca. 1,000 to 10,000 CFU of
streptococci/ml and 100 to 1,000 CFU of S. aureus/ml were
required to infect 50 to 100% of vegetations after bolus infec-
tion, whereas 2 to 10 CFU/ml were enough to achieve a com-
parable infection rate after continuous infusion was main-
tained for 10 h. This is particularly relevant for the risk of
developing streptococcal IE in view of the much greater
cumulative exposure (between 50 times and 5 million times) to
circulating bacteria during normal activity than after exposure
to sporadic dental procedures in humans (14, 32, 42, 43). In
practice, this results in a much smaller risk of IE (from 50 times
to 5 million times) in a setting of transient bacteremia than in
a situation of cumulative exposure.
This supports case-control studies demonstrating that most
cases of IE occurred outside the context of procedure-related
bacteremia (37, 39, 40). As a result, it helps clarify the debate
about antibiotic prophylaxis of IE, which is still ongoing, and
fully supports the drastic simplification of the newer guidelines
(15, 43, 44).
The case for S. aureus is more intricate. At least two situa-
tions should be taken into account, i.e., community-acquired S.
aureus bloodstream infection (BSI) and healthcare-associated
BSI (4). Community-acquired BSI without a detectable infec-
tion focus is often associated with IE. This means that the
observed BSI results from already established valve infection.
However, it does not provide information on how bacteria
accessed the blood and colonized the valve originally. This
could occur through repeated bouts of low-grade bacteremia,
induced, for instance, by skin breaches of injection of impure
material in the case of i.v. drug abuse.
In contrast, healthcare-associated BSI is often related to
primary colonization of i.v. devices with S. aureus, followed by
secondary infection of the valves. Here again, IE might results
from more or less prolonged low-grade staphylococcal dis-
charges from the colonized i.v. device rather that from massive
punctual bacterial injection. Thus, also somewhat speculative,
both of theses cases resemble more the low-grade continuous
infusion scenario than the transient high-grade bolus tested
herein.
For both oral streptococci and S. aureus, this model provides
a unique system to study more subtly the IE pathogenic fea-
tures, as well as new prevention measures that apply to cumu-
lative exposure to low bacterial numbers. Regarding pathogen-
esis, it is noteworthy that both bolus injection and continuous
infusion resulted, in particular for S. aureus, in similar infection
rates in the spleen. The fact that bacteria accumulated in this
TABLE 1. Bacterial densities in infected vegetations and spleens of animals 24 h after challenge with Streptococcus spp.
or S. aureus tested strainsa
Strain Inoculum (CFU/ml)
Median (range) log10 CFU/g in:
Vegetations Spleens
Bolus Continuous infusion Bolus Continuous infusion
S. intermedius 105 6.2 (3.5–7.7) 5.1 (4.7–8.1) 2.1 (1.7–2.5) 2.5 (1.7–3.4)
106 7.3 (7.1–7.6) 6.3 (3.4–7.6) 3.3 (3.0–3.6) 2.6 (1.8–3.2)
S. gordonii 105 7.6 (4.0–8.1) 6.2 (3.7–6.9) 2.9 (2.2–3.6) 3.1 (2.4–3.2)
106 7.8 (6.2–8.2) 6.4 (6.0–7.9) 3.3 (2.6–4.6) 3.0 (2.6–3.4)
MSSA Newman 103 8.5 (3.0–9.4) 8.3 (5.4–9.3) 2.5 (1.6–4.5) 3.2 (1.8–4.6)
104 9.4 (5.6–9.4) 8.8 (5.8–9.4) 3.9 (2.2–4.9) 4.5 (1.9–4.8)
MRSA P8 103 9.2 (4.6–9.4) 7.1 (6.1–9.3) 4.5 (1.7–4.9) 3.9 (1.7–4.7)
104 9.3 (5.2–9.6) 8.6 (4.1–9.6) 4.6 (2.6–4.8) 4.5 (1.7–4.7)
a Differences between values were not statistically different (P  0.05) as analyzed by the Mann-Whitney test.
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lymphoid organ suggests that recirculation might be an issue,
at least in the continuous-infusion group. Therefore, measures
that might enhance bacterial clearance from the spleen might
be useful for protection. For instance, preventing experimental
IE by immunization was not unanimously effective in former
experiments using bolus inoculation (5, 22, 30, 34, 35, 41). This
could be due to the fact that specific antibodies might become
overwhelmed in such acute conditions. In the light of the
present results, vaccination strategies could thus prove to be
much more effective in the more realistic low-gradient infec-
tion model, where levels of bacteremia are low. Likewise, anti-
aggregant strategies, which also displayed inconsistent results
(18, 26, 27), could become effective in this more chronic set-
ting. Indeed, due to a threshold effect, large bacterial numbers
could offset the efficacy of antibodies or moderate alterations
in bacterial or platelet adherence, which could become fully
active with lower numbers of circulating bacteria.
This is probably also true for other measures aimed at de-
creasing the likelihood of circulating bacteria, such as dental
hygiene and drainage of infected foci (15, 43, 44). Such long-
lasting interventions (e.g., vaccination or chronic anti-ag-
gregant therapy) are not unrealistic in the context of already-
approved preventing measures, such as anti-aggregant
prophylaxis of coronary diseases. However, demonstrating
their efficacy requires large cohort studies. Therefore, prior
demonstration in the present model could be useful. Finally,
one interesting observation that modulates somewhat the over-
all conclusion is the fact that at high inoculum sizes (e.g., 105
CFU for S. intermedius and 104 CFU for S. aureus P8) bolus
injection tends to be more infective than continuous infusion.
Although the difference was not statistically significant, this
finding converged with the observation by Strom et al. (37),
who reported a likely causality between procedures and IE
only in a small subgroup of patients with invasive dental ex-
traction and high-risk cardiac lesions. Newer guidelines also
advise antibiotic prophylaxis in these peculiar at-risk constel-
lations (15, 43, 44). Hence, this concordance further reinforces
the improved compatibility of this experimental model with
reality.
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